AOBiome Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • AOBiome's estimated annual revenue is currently $3.1M per year.(i)
  • AOBiome's estimated revenue per employee is $155,000

Employee Data

  • AOBiome has 20 Employees.(i)
  • AOBiome grew their employee count by 11% last year.

AOBiome's People

NameTitleEmail/Phone
1
CFO and SVP ManufacturingReveal Email/Phone
2
Inventor and FounderReveal Email/Phone
3
VP, Manufacturing Operations & QualityReveal Email/Phone
4
SVP Strategic Alliances and CommunicationsReveal Email/Phone
5
VP Research & DevelopmentReveal Email/Phone
6
Senior Director, Research & DevelopmentReveal Email/Phone
7
Chief Staff & Director Program ManagementReveal Email/Phone
8
Director, Manufacturing and Supply ChainReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M82-45%$107.3MN/A
#2
$0.2M1-50%N/AN/A
#3
$6.2M4021%N/AN/A
#4
$42.2M2184%$165MN/A
#5
$14.6M94-37%$312.8MN/A
#6
$0.3M2-67%N/AN/A
#7
$235M366-5%$340.9MN/A
#8
$56M289-7%$7.6MN/A
#9
$4.7M6136%N/AN/A
#10
$2M138%N/AN/A
Add Company

What Is AOBiome?

AOBiome Therapeutics, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing microbiome-based therapies for local, nasal and systemic inflammatory conditions. Founded in 2012 by PatientsLikeMe founder Jamie Heywood and MIT-trained Chemical Engineer David Whitlock, AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. The company's portfolio includes multiple clinical-stage programs: a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2a study to treat patients with adult eczema (atopic dermatitis), a Phase 2 study for the prevention of episodic migraines, and a Phase 1b/2a clinical trial for the treatment of allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications.

keywords:N/A

N/A

Total Funding

20

Number of Employees

$3.1M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

AOBiome News

2022-04-13 - Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference

AOBiome Therapeutics, a clinical stage biotechnology company focused on transforming human health by developing topical biologic therapies for...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.4M20-5%N/A
#2
$5M20-23%N/A
#3
$2M20N/AN/A
#4
$2M20N/AN/A
#5
$2M20N/AN/A